WO2000040560A1 - Amino-alcools et leur utilisation comme agonistes beta-3 adrenergiques - Google Patents

Amino-alcools et leur utilisation comme agonistes beta-3 adrenergiques Download PDF

Info

Publication number
WO2000040560A1
WO2000040560A1 PCT/JP1999/007203 JP9907203W WO0040560A1 WO 2000040560 A1 WO2000040560 A1 WO 2000040560A1 JP 9907203 W JP9907203 W JP 9907203W WO 0040560 A1 WO0040560 A1 WO 0040560A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydroxy
ammo
phenyl
mixture
alkyl
Prior art date
Application number
PCT/JP1999/007203
Other languages
English (en)
Inventor
Kiyoshi Taniguchi
Minoru Sakurai
Takeshi Kato
Naoaki Fujii
Kenichi Washizuka
Yasuyo Tomishima
Hisashi Takasugi
Yutaka Kohno
Nobuhiro Yamamoto
Naoko Tanimura
Hirohumi Ishikawa
Original Assignee
Fujisawa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co., Ltd. filed Critical Fujisawa Pharmaceutical Co., Ltd.
Priority to EP99961305A priority Critical patent/EP1140849A1/fr
Priority to JP2000592269A priority patent/JP2002534415A/ja
Publication of WO2000040560A1 publication Critical patent/WO2000040560A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • C07D213/6432-Phenoxypyridines; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/20Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated the carbon skeleton being saturated and containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/80Acids; Esters in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84Nitriles
    • C07D213/85Nitriles in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/233Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D219/00Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/06Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Definitions

  • This invention relates to new aminoalcohol derivatives and salts thereof.
  • new aminoalcohol derivatives and salts thereof which act as selective j33 adrenergic receptor agonists and therefore have gut selective sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic, anti-urinary incontinence and anti-pollakiuria activities, to processes for the preparation thereof, to a pharmaceutical composition comprising the same and to a method of using the same therapeutically in the treatment and/or prevention of gastro-intestinal disorders caused by smooth muscle contractions in human beings or animals, and more particularly to a method for the treatment and/or prevention of spasm or hyperanakinesia in case of irritable bowel syndrome, gastritis, gastric ulcer, duodenal ulcer, enteritis, cholecystopathy, cholangitis, urinary calculus and the like; for the treatment and/or prevention of ulcer such as gastric ulcer, duodenal ulcer, peptic ulcer, ulcer caused by non steroidal anti-inflammatory drugs, or the like;
  • One object of this invention is to provide new and useful aminoalcohol derivatives and salts thereof which have gut selective sympathomimetic, anti-ulcerous, lipolytic, anti-urinary incontinence and anti-pollakiuria activities.
  • Another object of this invention is to provide processes for the preparation of said aminoalcohol derivatives and salts thereof.
  • a further object of this invention is to provide a pharmaceutical composition comprising, as an active ingredient, said aminoalcohol derivatives and salts thereof.
  • Still further object of this invention is to provide a therapeutical method for the treatment and/or prevention of aforesaid diseases in human beings or animals, using said aminoalcohol derivatives and salts thereof.
  • X ⁇ _ is bond or -OCH 2 - ⁇
  • X 2 is -(CH2- n -, in which n is 1, 2 or 3;
  • X3 is bond, -0-, -S-, -OCH 2 * or -NH-
  • R ,1 x is phenyl or pyridyl, each of which may be substituted with one or two substituent (s) selected from the group consisting of hydroxy, halogen, amino, [ (lower) alkylsulfonyl] amino, nitro, benzyloxycarbonylamino and benzyloxy; R is hydrogen, (lower) alkoxycarbonyl, benzyl or benzyloxycarbonyl ;
  • R is hydroxy (lower) alkyl, (lower) alkoxy (lower) alkyl or halo (lower ) alkyl;
  • R ⁇ is aryl or an unsaturated heterocyclic group containing nitrogen, each of which may be substituted with one or two substituent (s) selected from the group consisting of hydroxy, lower alkyl, lower alkoxy, halo ( lower) alkyl, halogen, hydroxy (lower) alkyl, (lower) alkoxy (lower) alkyl, cyano, carboxy, (lower) alkoxycarbonyl, lower alkanoyl, carbamoyl, (mono or di) (lower) - alkylcarbamoyl, [ (lower) alkylsulfonyl] carbamoyl, amino, nitro, ureido, [ (lower) alkylcarbonyl] amino, [ (lower ) alkylsulfonyl] amino and (arylsulfonyl) amino, and a salt thereof.
  • substituent selected from the group consisting of hydroxy, lower alkyl, lower alkoxy,
  • the object compound [I] or a salt thereof can be prepared by the following processes.
  • Rfj and R are each ammo protective group, Q is protected hydroxy
  • X is halogen, and is aryl or an unsaturated heterocyclic group containing nitrogen, each of which may be substituted with one or two substituent (s) selected from the group consisting of hydroxy, lower alkyl, lower alkoxy, halo (lower) alkyl, halogen, hydroxy (lower) alkyl, (lower ) alkoxycarbonyl, lower alkanoyl, carbamoyl, (mono or di) (lower) - alkylcarbamoyl, [ (lower) alkylsulfonyl ] carbamoyl, amino nitro, ureido, [ (lower) alkylcarbamoyl ] amino,
  • lower is intended to mean a group having 1 to 6 carbon atom(s), unless otherwise provided.
  • Suitable "lower alkyl” and “lower alkyl” moiety in the terms of "[ (lower) alkylsulfonyl] amino” , "hydroxy (lower) - alkyl”, etc. may include straight or branched one having 1 to 6 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl,
  • Suitable "lower alkoxy” and “lower alkoxy” moiety in the terms of " (lower) alkoxycarbonyl” , “ (lower) alkoxy (lower) - alkyl”, etc. may be a straight or branched one such as methoxy, ethoxy, propoxy, isopropoxy, 1-ethylpropoxy, butoxy, sec-butoxy, tert-butoxy, pentyloxy, neopentyloxy, tert-pentyloxy, hexyloxy, and the like, in which the preferred one may be C- ⁇ -C ⁇ alkoxy, and the most preferred one may be methoxy.
  • Suitable “lower alkanoyl” may include formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2,2- dimethylpropanoyl, hexanoyl and the like.
  • Suitable "halogen” may be fluoro, chloro, bromo and iodo.
  • Suitable "aryl” and “aryl” moiety in the term of " (arylsulfonyl ) amino" may include phenyl, naphthyl, anthryl, and the like, in which the preferred one may be phenyl.
  • Suitable "an unsaturated heterocyclic group containing nitrogen” may include an unsaturated, monocyclic or polycyclic heterocyclic group containing at least one nitrogen atom. And especially preferable unsaturated heterocyclic group containing nitrogen may be ones such as an unsaturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl and its N-oxide, dihydropyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1,2,4- triazolyl, 1H-1, 2 , 3-triazolyl, 2H-1, 2, 3-triazolyl, etc.), tetrazolyl (e.g., lH-tetrazolyl, 2H-tetrazoly
  • Suitable "hydroxy protective group” in the term “protected hydroxy” may include commonly protective group or the like.
  • Suitable common protective group may include acyl as mentioned below, mono (or di or tri) phenyl (lower) alkyl which may have one or more suitable substituent (s) (e.g. benzyl, 4- methoxyphenyl, trityl, etc.), trisubstituented silyl [e.g., tri (lower) alkylsilyl (e.g., trimethylsilyl; t-butyldimethylsilyl, etc.], tetrahydropyranyl and the like.
  • suitable substituent e.g. benzyl, 4- methoxyphenyl, trityl, etc.
  • trisubstituented silyl e.g., tri (lower) alkylsilyl (e.g., trimethylsilyl; t-butyldimethylsilyl, etc.]
  • Suitable "acyl” may include carbamoyl, aliphatic acyl group and acyl group containing an aromatic ring, which is referred to as aromatic acyl, or heterocyclic ring, which is referred to as heterocyclic acyl.
  • acyl may be illustrated as follows; carbamoyl; carboxy; aliphatic acyl such as lower or higher alkanoyl (e.g., formyl, acetyl, propanoyl, butanoyl, 2- methylpropanoyl, pentanoyl, 2, 2-dimethylpropanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl, heptadecanoyl , octadecanoyl, nonadecanoyl, icosanoyl, etc.); cyclo ( lower) alkylcarbonyl (e.g., cyclopropylcarbonyl, cyclobutyl
  • Aromatic acyl such as aroyl (e.g., benzoyl, toluoyl, naphthoyl, etc.); ar (lower) alkanoyl [e.g., phenyl (lower) alkanoyl (e.g., phenylacetyl, phenylpropanol, phenylbutanoyl , phenylisobutanoyl, phenylpentanoyl, phenylhexanoyl, etc.), naphthtyl (lower) alkanoyl (e.g., naphthylacetyl, naphthylpropanoyl, naphthylbutanoyl, naphthylisobutanoyl, etc.); ar (lower) alkenoyl [e.g., phenyl (lower) alkenoyl (e.g., phenylpropenoyl, phen
  • Heterocyclic acyl such as heterocyclic carbonyl; heterocyclic (lower) alkanoyl (e.g., heterocyclicacetyl, heterocyclicpropanoyl, heterocyclicbutanoyl, heterocyclicpentanoyl, heterocyclichexanoyl, etc.); heterocyclic (lower) alkenoyl (e.g., heterocyclicpropenoyl, heterocyclicbutenoyl, heterocyclicpentenoyl, heterocyclichexenoyl, etc.); heterocyclicglyoxyloyl; or the like; and the like.
  • heterocyclic (lower) alkanoyl e.g., heterocyclicacetyl, heterocyclicpropanoyl, heterocyclicbutanoyl, heterocyclicpentanoyl, heterocyclichexanoyl, etc.
  • heterocyclic (lower) alkenoyl e.g., heterocyclicpropenoyl, hetero
  • Amino protective groups in the context of the invention are the customary amino protective groups used in peptide chemistry. These include benzyloxycarbonyl, 2, 4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, allyloxycarbonyl, phthaloyl, 2, 2, 2-trichloroethoxycarbonyl, fluorenyl-9-methoxycarbonyl, formyl, acetyl, 2-chloroacetyl, 2, 2, 2-trifluoroacetyl, 2, 2, 2-trichloroacetyl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, phthalimido, isovaleroyl or benzyloxymethylene, 4-nitrobenzyl, 2, 4-dinitobenzyl, 4-nitrophenyl, 4-methoxyphenyl, triphen
  • Suitable salts of the object aminoalcohol derivatives [I] are pharmaceutically acceptable salts and include conventional non-toxic salts such as an inorganic acid addition salt [e.g. hydrochloride, hydrobromide, sulfate, phosphate, etc.], an organic acid addition salt [e.g. formate, acetate, trifluoroacetate, oxalate, maleate, fumarate, tartrate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.], an alkali metal salt [e.g. sodium salt, potassium salt, etc.] or the like.
  • an inorganic acid addition salt e.g. hydrochloride, hydrobromide, sulfate, phosphate, etc.
  • an organic acid addition salt e.g. formate, acetate, trifluoroacetate, oxalate, maleate, fumarate, tartrate, methanesulfonate, benzen
  • Preferred embodiments of the object compound [I] are as follows:
  • X ⁇ is bond or -0CH 2 -;
  • X 2 is -(CH 2 ) n - in which n is 1;
  • X 3 is -0-
  • R-i is phenyl which may be substituted with one or two substituent (s) selected from the group consisting of halogen, nitro, amino, benzyloxy, benzyloxycarbonylamino, hydroxy and loweralkylsulfonylamino; or pyridyl which may have amino.
  • R 2 is hydrogen.
  • R is hydroxy (lower) alkyl
  • R4 is pyridyl which may be substituted with carbamoyl, lower alkoxycarbonyl, carboxy, cyano, nitro, amino, hydroxy (lower) alkyl, mono (or di) (lower) - alkylcarbamoyl, lower alkyl, halogen, lower alkylsulfonylamino, phenylsulfonylamino or lower alkanoyl; phenyl which may be substituted with halogen; quinolyl which may be substituted with lower alkoxycarbonyl, nitro, carbamoyl, carboxy, halogen or lower alkoxy; naphthyl; benzothiazolyl; pyridyl N-oxide; pyrimidinyl; naphthyridinyl; pyrazinyl; imidazo [1 , 2-a] pyridyl ; quinoxalinyl which may be substituted with halogen; acridinyl
  • More preferred embodiment of the object compound [I] are llows: X j _ is bond or -OCH 2 -;
  • X 2 is ⁇ (CH 2m- -"- n n i cl1 n i- s 1 ;
  • X 3 is -0-;
  • R is phenyl which may be substituted with one or two substituent (s) selected from the group consisting of halogen, nitro, amino, benzyloxy, benzyloxycarbonylamino, hydroxy and lower alkylsulfonylamino;
  • R 2 is hydrogen;
  • R3 is hydroxy (lower) alkyl ; and R ⁇ is pyridyl which may be substituted with carbamoyl, lower alkoxycarbonyl, carboxy, cyano, nitro, amino, hydroxy (lower) alkyl, mono (or di) (lower ) alkylcarbamoyl, lower alkyl, halogen, lower alkylsulfonylamino, phenylsulfonylamino or lower alkanoyl; phenyl which may be substituted with halogen; quinolyl which may be substituted with lower alkoxycarbonyl, nitro, carbamoyl, carboxy, halogen or lower alkoxy; naphthyl; benzothiazolyl; pyridyl N-oxide; pyrimidinyl; naphthyridinyl; pyrazinyl; imidazo [ 1 , 2-a] pyridyl; quinoxalinyl which may be
  • More preferred embodiment of the object compound [I] are as follows:
  • X- ] _ is bond or -OCH 2 ⁇ ;
  • X is ⁇ (CH ) n - in which n is 1;
  • X 3 is -0-;
  • R ⁇ is pyridyl which may have amino;
  • R 2 is hydrogen;
  • R3 is hydroxy ( lower) alkyl
  • R4 is pyridyl which may have hydroxy (lower) alkyl .
  • the object compound [I] or a salt thereof can be prepared by reacting a compound [II] with a compound [III] or a salt thereof.
  • Suitable salt of the compound [III] may be the same as those exemplified for the compound [I].
  • the reaction is preferably carried out in the presence of a base such as an alkali metal carbonate [e.g. sodium carbonate, potassium carbonate, etc.], an alkaline earth metal carbonate [e.g. magnesium carbonate, calcium carbonate, etc.], an alkali metal bicarbonate [e.g. sodium bicarbonate, potassium bicarbonate, etc.], tri (lower) alkylamine [e.g. trimethylamine, triethylamine, etc.], picoline or the like.
  • a base such as an alkali metal carbonate [e.g. sodium carbonate, potassium carbonate, etc.], an alkaline earth metal carbonate [e.g. magnesium carbonate, calcium carbonate, etc.], an alkali metal bicarbonate [e.g. sodium bicarbonate, potassium bicarbonate, etc.], tri (lower) alkylamine [e.g. trimethylamine, triethy
  • the reaction is usually carried out in a conventional solvent, such as an alcohol [e.g. methanol, ethanol, propanol, isopropanol, etc.], diethyl ether, tetrahydrofuran, dioxane, or any other organic solvent which does not adversely influence the reaction.
  • a conventional solvent such as an alcohol [e.g. methanol, ethanol, propanol, isopropanol, etc.], diethyl ether, tetrahydrofuran, dioxane, or any other organic solvent which does not adversely influence the reaction.
  • the reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
  • the object compound [lb] or a salt thereof can be prepared by subjecting a compound [la] or a salt thereof to elimination reaction of the amino protective group.
  • Suitable salts of the compounds [la] and [lb] may be the same as those exemplified for the compound [I].
  • This reaction can be carried out in the manner disclosed in Example 8 or Example 30, or similar manners thereto.
  • the object compound [Ic] or a salt thereof can be prepared by reacting a compound [III] or a salt thereof with a compound [IV] .
  • Suitable salts of the compound [III] may be the same as those exemplified for the compound [I].
  • the reaction can be carried out in the presence of the base such as an alkali metal carbonate [e.g., sodium carbonate, potassium carbonate, etc.], an alkaline earth metal carbonate [e.g., magnesium carbonate, calcium carbonate, etc.], an alkali metal bicarbonate [e.g., sodium bicarbonate, potassium bicarbonate, etc.], tri (lower) alkylamine [e.g., trimethylamine, triethylamine, etc.], picoline or the like.
  • the base such as an alkali metal carbonate [e.g., sodium carbonate, potassium carbonate, etc.], an alkaline earth metal carbonate [e.g., magnesium carbonate, calcium carbonate, etc.], an alkali metal bicarbonate [e.g., sodium bicarbonate, potassium bicarbonate, etc.], tri (lower) alkylamine [e.g., trimethyl
  • the reaction is usually carried out in a conventional solvent, such as an alcohol [e.g., methanol, ethanol, propanol, isopropanol, etc.], diethyl ether, tetrahydrofuran, dioxane, or any other organic solvent which does not have adverse effect on the reaction.
  • a conventional solvent such as an alcohol [e.g., methanol, ethanol, propanol, isopropanol, etc.], diethyl ether, tetrahydrofuran, dioxane, or any other organic solvent which does not have adverse effect on the reaction.
  • the reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
  • the reaction can also be carried out in the manner disclosed in Example 72 or similar manner thereof.
  • the object compound [Id] or a salt thereof can be prepared by reacting a compound [V] or a salt thereof with a compound [VI ] .
  • Suitable salts of the compound [V] may be the same as those exemplified for the compound [I].
  • reaction can also be carried out in the manner disclosed in Example 78 or similar manners thereto.
  • the compounds obtained by the above processes can be isolated and purified by a conventional method such as pulverization, recrystallization, column chromatography, reprecipitation, or the like, and converted to the desired salt in conventional manners, if necessary.
  • the compound [I] and the other compounds may include one or more stereoisomers due to asymmetric carbon atoms, and all of such isomers and mixture thereof are included within the scope of this invention. It is further to be noted that isomerization or rearrangement of the object compound [I] may occur due to the effect of the light acid, base or the like, and the compound obtained as the result of said isomerization or rearrangement is also included within the scope of the present invention. It is also to be noted that the solvating form of the compound [I] (e.g. hydrate, etc.) and any form of the crystal of the compound [I] are included within the scope of the present invention.
  • the object compound [I] or a salt thereof possesses gut selective sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic and anti-pollakiuria activities, and are useful for the treatment and/or prevention of gastrointestinal disorders caused by smooth muscle contractions in human beings or animals, and more particularly to methods for the treatment and/or prevention of spasm or hyperanakinesia in case of irritable bowel syndrome, gastritis, gastric ulcer, duodenal ulcer, enteritis, cholecystopathy, cholangitis, urinary calculus and the like; for the treatment and/or prevention of ulcer such as gastric ulcer, duodenal ulcer, peptic ulcer, ulcer causes by non steroidal anti-inflammatory drugs, or the like; for the treatment and/or prevention of dysuria such as pollakiuria, urinary incontinence or the like in case of nervous pollakiuria, neurogenic bladder dysfunction, nocturia, unstable bladder, cystospasm, chronic cystitis, chronic prost
  • the object compound (I) or a pharmaceutically acceptable salt thereof can be usually administered to mammals including human being in the form of a conventional pharmaceutical composition such as capsule, micro-capsule, tablet, granule, powder, troche, syrup, aerosol, inhalation, solution, injection, suspension, emulsion, suppository or the like.
  • the effective ingredient may usually be administered with a unit dose of 0.01 mg/kg to 50 mg/kg, one to four times a day. However, the above dosage may be increased or decreased according to age, weight, conditions of patients or methods of administration.
  • the organic layer was washed with brine, dried over sodium sulfate, and evaporated in vacuo.
  • the residue was dissolved in ethanol, and treated with aqueous sodium hydrogen sulfite for 10 minutes. After evaporation in vacuo and partition between ethyl acetate and water, the aqueous layer was made basic with aqueous sodium carbonate and extracted with ethyl acetate twice. The organic layer was washed with brine, dried over sodium sulfate, and evaporated in vacuo.
  • N, N-dimethylformamide (10 ml) was stirred at room temperature for 9 hours.
  • the mixture was diluted with ethyl acetate and poured into water.
  • the organic layer was washed with aqueous 10% potassium hydrogensulfate and brine, dried over sodium sulfate and evaporated in vacuo.
  • Example 7 Under nitrogen, to a solution of [(2R)-2-(3- chlorophenyl) -2-hydroxyethyl] [ ( IS) -1- [ 4- ( 3-formylpyr ⁇ dm-2- yloxy) benzyl] -2-hydroxyethyl ] carbamic acid tert-butyl ester (0.24 g) in methanol (4.5 ml) was added sodium borohydride (17 mg) at 5°C, and the mixture was stirred at the same temperature for 10 minutes. The mixture was evaporated in vacuo. To the residue was added water and extracted with ethyl acetate. The organic layer was washed with brme, dried over sodium sulfate, and evaporated in vacuo.
  • Example 8 To a solution of [ (2R) -2- ( 3-chlorophenyl ) -2- hydroxyethyl] [ (IS) -2-hydroxy-l- [4- ( 3-hydroxymethylpy ⁇ dm-2- yloxy) benzyl] ethyl] carbamic acid tert-butyl ester (0.14 g) in ethyl acetate (5.2 ml) was added 4N hydrogen chloride in ethyl acetate (1.3 ml) and the resulting mixture was allowed to stand at room temperature for 2 hours. The mixture was evaporated in vacuo. To the residue was added aqueous saturated sodium bicarbonate and extracted with ethyl acetate. The organic layer was washed with brme, dried over sodium sulfate, and evaporated in vacuo. The residue was purified by column chromatography on silica gel
  • Example 11 A mixture of 6- [ 4- [ (2S) -2- [ (2R) -2- ( 3-chlorophenyl ) -2- hydroxyethylammo] -3-hydroxypropyl] phenoxy] nicotinic acid methyl ester dihydrochloride (0.26 g) and aqueous 28% ammonium hydroxide (26 ml) in 1,4-dioxane (5.2 ml) was stirred at room temperature for 1 day. The mixture was evaporated in vacuo, followed by partition between ethyl acetate and water.
  • 6- [4- [ (2S) -2- [ (2R) -2- (3-Chlorophenyl) -2-hydroxyethylammo] -3- hydroxypropyl ] phenoxy] nicotmamide was treated with 4N hydrogen chloride in ethyl acetate, followed by crystallization from methanol-ethyl acetate to give 6- [4- [ (2S) -2- [ (2R) -2- (3-chlorophenyl) -2-hydroxyethylammo] -3- hydroxypropyl ] phenoxy] nicotmamide dihydrochloride (57 mg) .
  • Example 13 To a solution of 6- [ 4- [ (2S) -2- [ (2R) -2- ( 3-chlorophenyl ) - 2-hydroxyethylammo] -3-hydroxypropyl] phenoxy] nicotmic acid methyl ester dihydrochloride (0.18 g) in methanol (3.6 ml) was added with aqueous IN sodium hydroxide (1.4 ml), and the mixture was stirred at room temperature for 4.5 hours. To the mixture was added aqueous IN hydrogen chloride (1.2 ml) and evaporated m vacuo.
  • Example 14 Under nitrogen, a solution of (S) -2-am ⁇ no-3- [4- (3, 5- d ⁇ chloropyr ⁇ dm-4-yloxy) phenyl] propan-1-ol hydrochloride (0.39 g) , (R) -3-chlorostyrene oxide (0.50 g) and N,N- dnsopropylethylamme (0.19 ml) in a mixture of methanol (1 ml) and 1,4-dioxane (1 ml) was refluxed for 14.5 nours . The mixture was evaporated in vacuo.
  • Example 16 Under nitrogen, a suspension of (S)-4-[4-(6- chloropy ⁇ dm-2-yloxy) benzyl ] oxazol ⁇ dm-2-one (0.49 g) , (R)- 3-chlorostyrene oxide (0.49 g) and potassium carbonate (0.44 g) in N, N-dimethylformamide (4.9 ml) was stirred at 80°C for 96 hours. The mixture was diluted with ethyl acetate and insoluble materials were filtered off. The filtrate was evaporated in vacuo. The residue was dissolved in a mixture of ethanol (8 ml) and water (7 ml) .
  • Example 18 To a solution of ( 4S) -3- [ (2R) -2- ( 3-chlorophenyl) -2- hydroxyethyl]-4-[4-(py ⁇ dm-2-yloxy)benzyl]oxazol ⁇ dm-2-one (0.67 g) in ethanol (6.7 ml) was added aqueous 4N sodium hydroxide (4 ml), and the mixture was refluxed for 2 hours. After evaporation in vacuo and partition between water and ethyl acetate, the organic layer was washed with brme, dried over sodium sulfate, and evaporated m vacuo.
  • Example 25 Under nitrogen, a solution of 2- [4- [ (2S) -2- [ (2S) -2- hydroxy-3-phenoxypropylammo] -3-hydroxypropyl ] phenoxy] - nicotmonitrile (3.0 g) , di-tert-butyl dicarbonate (1.8 g) in tetrahydrofuran (20 ml) was stirred at room temperature for 9 hours.
  • Example 34 The following compound was synthesized according to a similar manner to that of Example 33.
  • Example 39 To a solution of (2S) -2- ( (2S) -2-hydroxy-3-pnenoxypropyl- amino) -3- [4- ( 3-n ⁇ tropy ⁇ dm-2-yloxy) phenyl] propanol (100 mg) in dioxane (3 ml) was added 4N hydrogen chloride in dioxane (3 ml) at room temperature, and the solution was stirred at the same temperature for 3 hours.
  • Example 42 A mixture of 2- (4- ⁇ 3-hydroxy- (2S) -2- [ (2S) -2-hydroxy-3- ( 4-benzyloxyphenoxy) propylamino] propyl ⁇ phenoxy) nicotmamide (150 mg) , 10% palladium on activated carbon (50% wet, 50 mg) and methanol (10.0 ml) was stirred at room temperature in the presence of hydrogen at an atmospheric pressure for 1 hour, and filtered. The filtrate was evaporated m vacuo.
  • Example 55 A mixture of N- [2-benzyloxy-5- (( IR) -l-hydroxy-2- IS) -1- nydroxymethyl-2- [ 4- (qumolm-3-yloxy) phenyl] ethylammo ⁇ - ethyl) phenyl ] methanesulfonamide (20 mg) and 10% palladium on activated carbon (50% wet, 10 mg) in methanol (3 ml) was stirred at room temperature in the presence of hydrogen at an atmospheric pressure for 2 hours.
  • Example 60 The following compound was obtained according to a similar manner to that of Example 55.
  • Example 61 The following compounds were obtained according to a similar manner to that of Example 53.
  • the organic layer was dried over anhydrous magnesium sulfate and evaporated in vacuo.
  • To the residue was added 4N hydrogen chloride in 1,4- dioxane in order to decompose the boran complexes, followed by evaporation in vacuo.
  • the residue was dissolved into a mixture of saturated aqueous sodium hydrogencarbonate and dichloromethane. After separation, the organic layer was dried over anhydrous magnesium sulfate and evaporated in vacuo.
  • Potassium hydroxide powder (85% purity, 35.3 mg, 0.535 mmol) was added to dimethyl sulfoxide (5.0 ml) at room temperature and the mixture was stirred at the same temperature for 1 hour.
  • 4-chloroqu ⁇ nolme (103 mg, 0.203 mmol) in dimethyl sulfoxide (0.5 ml) was added and the mixture was stirred at 100°C for 5 hours.
  • Potassium hydroxide powder (85% purity, 53.4 mg, 0.809 mmol) was added to dimethyl sulfoxide ( 6.0 ml ) at room temperature and the mixture was stirred at the same temperature for 80 minutes.
  • 4- [ (2S) -2- [benzyl [ (2S) -2-hydroxy-3-phenoxypropyl ] ammo] -3- hydroxypropyl] phenol 300 mg, 0.736 mmol
  • 4-chloro-7-methoxyqumolme (171 mg, 0.883 mmol) was added and the mixture was stirred at 100°C for 3.5 hours.
  • Potassium hydroxide powder (85% purity, 53.4 mg, 0.809 mmol) was added to dimethyl sulfoxide (6.0 ml) at room temperature and the mixture was stirred at the same temperature for 1 hour.
  • dimethyl sulfoxide 6.0 ml
  • 4-[(2S)-2- [benzyl [ (2S) -2-hydroxy-3-phenoxypropyl ] ammo] -3-hydroxypropyl] phenol 300 mg, 0.736 mmol
  • 4-chloro-6-fluoroqumolme 160 mg, 0.881 mmol was added and the mixture was stirred at 100°C for 24 hours.
  • Example 81 Potassium hydroxide powder (85% purity, 55.0 mg, 0.833 mmol) was added to dimethyl sulfoxide ( 8.0 ml ) at room temperature and the mixture was stirred at the same temperature for 1 hour. To the mixture was added 4-[(2S)-2- [benzyl [ (2R) -2- ( 4-benzyloxy-3-n ⁇ trophenyl ) -2-hydroxyethyl] - ammo] -3-hydroxypropyl] phenol (400 mg, 0.757 mmol) and stirred for 40 minutes. Further, 4-chloro-6-fluoroquinol e (179 mg, 0.986 mmol) was added and the mixture was stirred at 100°C for 96 hours.
  • reaction mixture was warmed to room temperature and stirred for 15 minutes.
  • the reaction mixture was diluted with ethyl acetate (10 ml) and washed with water (10 ml x 2), brme (10 ml x 1), dried over magnesium sulfate. Evaporation of the solvent gave an orange foam (97.6 mg) .
  • Example 88 The following compound was obtained by a similar manner to that of Example 94 followed by a reduction of the nitro group as described in Example 88.
  • Example 95 A mixture of 2- ⁇ 4- [ (2S) -3-hydroxy-2- ( (2S) -2-hydroxy-3- phenoxypropylammo) propyl] phenoxy ⁇ qumolme-3-carboxylic acid methyl ester (270 mg) and aqueous 28% ammonium hydroxide (5.0 ml) m 1,4-dioxane (5.0 ml) was stirred at room temperature for 2 days. The mixture was evaporated in vacuo, followed by partition between ethyl acetate and water. The organic layer was washed with brme, dried over sodium sulfate and evaporated in vacuo.

Abstract

L'invention concerne un composé de formule (I), dans laquelle X1 est une liaison ou OCH2; X2 est (CH2)n, où n est 1, 2 ou 3; X3 est une liaison, O, S, OCH2 ou NH; R1 est phényle ou pyridyle, chacun pouvant comporter un ou deux substituants choisis dans le groupe comprenant hydroxy, halogène, etc.; R2 est hydrogène, alcoxycarbonyle (inférieur), etc.; R3 est hydroxyalkyle (inférieur), haloalkyle (inférieur), etc.; R4 est aryle ou un groupe hétérocyclique insaturé, chacun pouvant comporter un ou deux substituants choisis dans le groupe comprenant alkyle inférieur, hydroxy, carbamoyle, halogène, alcoxy inférieur, etc.; ainsi qu'un sel dudit composé, qui est utile comme médicament.
PCT/JP1999/007203 1998-12-30 1999-12-22 Amino-alcools et leur utilisation comme agonistes beta-3 adrenergiques WO2000040560A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP99961305A EP1140849A1 (fr) 1998-12-30 1999-12-22 Amino-alcools et leur utilisation comme agonistes beta-3 adrenergiques
JP2000592269A JP2002534415A (ja) 1998-12-30 1999-12-22 新規化合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP7967A AUPP796798A0 (en) 1998-12-30 1998-12-30 New compound
AUPP7967 1998-12-30

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09868615 A-371-Of-International 2001-06-22
US10/118,929 Continuation US20020143034A1 (en) 1998-12-20 2002-04-10 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists

Publications (1)

Publication Number Publication Date
WO2000040560A1 true WO2000040560A1 (fr) 2000-07-13

Family

ID=3812174

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1999/007203 WO2000040560A1 (fr) 1998-12-30 1999-12-22 Amino-alcools et leur utilisation comme agonistes beta-3 adrenergiques

Country Status (4)

Country Link
EP (1) EP1140849A1 (fr)
JP (1) JP2002534415A (fr)
AU (1) AUPP796798A0 (fr)
WO (1) WO2000040560A1 (fr)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001035947A2 (fr) * 1999-11-15 2001-05-25 Eli Lilly And Company Traitement des syndromes cachectiques au moyen de propanolamines aryloxy
WO2002000622A2 (fr) * 2000-06-27 2002-01-03 Fujisawa Pharmaceutical Co., Ltd. Nouveaux derives d'aminoalcool
WO2002024635A2 (fr) * 2000-09-25 2002-03-28 Fujisawa Pharmaceutical Co., Ltd. Derives d'aminoalcool
EP1292564A2 (fr) * 2000-02-28 2003-03-19 Fujisawa Pharmaceutical Co., Ltd. Derive d'aminoalcool
US6653323B2 (en) * 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
US6670376B1 (en) 2001-11-13 2003-12-30 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
US6689888B2 (en) 2002-02-27 2004-02-10 Pfizer Inc. Processes and intermediates useful in preparing β3-adrenergic receptor agonists
US6689800B2 (en) 2002-02-27 2004-02-10 Pfizer Inc. β3-adrenergic receptor agonist crystal forms, processes for the production thereof, and uses thereof
WO2004026817A1 (fr) * 2002-09-19 2004-04-01 Kyorin Pharmaceutical Co., Ltd. Derive d'amino-alcool, sel d'addition de ce dernier et immunosuppresseur
WO2004026305A1 (fr) * 2002-09-19 2004-04-01 Eli Lilly And Company Diaryle ethers utilises en tant qu'antagonistes de recepteur opioides
US6730792B2 (en) 2000-07-13 2004-05-04 Eli Lilly And Company β3 adrenergic agonists
WO2004080996A1 (fr) * 2003-03-07 2004-09-23 Eli Lilly And Company Antagonistes des recepteurs opioides
US6825220B2 (en) 2000-11-10 2004-11-30 Eli Lilly And Company 3-Substituted oxindole β 3 agonists
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
US6911463B2 (en) 2001-08-14 2005-06-28 Eli Lilly And Company 3-substituted oxindole β-3 agonists
WO2005066164A1 (fr) * 2003-12-22 2005-07-21 Eli Lilly And Company Antagonistes de recepteur d'opioides
US7009060B2 (en) 2002-01-11 2006-03-07 Eli Lilly And Company 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists
DE102004050952A1 (de) * 2004-10-18 2006-04-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung von Beschwerden, die mit krankhaften Veränderungen oder Irritationen der Prostata verbunden sind
US7071208B2 (en) 2001-11-20 2006-07-04 Eli Lilly And Company β3 Adrenergic agonists
US7205407B2 (en) 2001-11-20 2007-04-17 Eli Lilly And Company 3-Substituted oxindole β3 agonists
US7208505B2 (en) 2001-08-14 2007-04-24 Eli Lilly And Company β3 adrenergic agonists
WO2007078523A2 (fr) * 2005-12-15 2007-07-12 Astrazeneca Ab Composes d'oxazolidinone et leur utilisation en tant que potentialisateurs de recepteur de glutamate metabotropique
US7317023B2 (en) 2004-07-21 2008-01-08 Theravance, Inc. Diaryl ether β2 adrenergic receptor agonists
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
US7884110B2 (en) 2007-07-12 2011-02-08 Chemocentryx, Inc. Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
US7977334B2 (en) 2004-04-30 2011-07-12 Boehringer Ingelheim International Gmbh Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
US10758540B2 (en) 2017-10-11 2020-09-01 Chemocentryx, Inc. Treatment of focal segmental glomerulosclerosis with CCR2 antagonists
US10973809B2 (en) 2016-11-23 2021-04-13 Chemocentryx, Inc. Method of treating focal segmental glomerulosclerosis

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL373429A1 (en) * 2002-07-17 2005-08-22 Lek Pharmaceuticals D.D. Novel derivatives of pyridylethanol (phenylethyl) amines as inhibitors of cholesterol biosynthesis, processes for their preparation, and pharmaceutical compositions containing them
JPWO2006041015A1 (ja) * 2004-10-12 2008-05-15 杏林製薬株式会社 アミノアルコール誘導体とその付加塩及び免疫抑制剤
WO2009099174A1 (fr) 2008-02-07 2009-08-13 Kyorin Pharmaceutical Co., Ltd. Agent thérapeutique ou agent préventif pour maladie inflammatoire des intestins contenant un dérivé d'alcool aminé comme composant actif
CN102863345A (zh) * 2011-07-06 2013-01-09 中国医学科学院药物研究所 胺基丙二醇类衍生物、其制备方法和其药物组合物与用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0318092A2 (fr) * 1987-11-27 1989-05-31 Merck & Co. Inc. Agonistes bêta-adrénergiques
EP0659737A2 (fr) * 1993-12-21 1995-06-28 Bristol-Myers Squibb Company Substituts pour Catécholamines utiles comme agonistes B3
EP0714883A1 (fr) * 1994-12-02 1996-06-05 Bristol-Myers Squibb Company Aryloxypropanolamines en tant qu' agonistes de récepteur bêta 3 adrénergique
EP0764632A2 (fr) * 1995-09-21 1997-03-26 Eli Lilly And Company Agonistes sélectifs bêta3-adrénergiques
EP0764640A1 (fr) * 1995-09-21 1997-03-26 Eli Lilly And Company Agonistes adrénergiques bêta-3 spécifiques
EP0801060A1 (fr) * 1996-04-09 1997-10-15 Pfizer Inc. Des agonistes bèta-3 adrénergiques hétérocycliques

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0318092A2 (fr) * 1987-11-27 1989-05-31 Merck & Co. Inc. Agonistes bêta-adrénergiques
EP0659737A2 (fr) * 1993-12-21 1995-06-28 Bristol-Myers Squibb Company Substituts pour Catécholamines utiles comme agonistes B3
EP0714883A1 (fr) * 1994-12-02 1996-06-05 Bristol-Myers Squibb Company Aryloxypropanolamines en tant qu' agonistes de récepteur bêta 3 adrénergique
EP0764632A2 (fr) * 1995-09-21 1997-03-26 Eli Lilly And Company Agonistes sélectifs bêta3-adrénergiques
EP0764640A1 (fr) * 1995-09-21 1997-03-26 Eli Lilly And Company Agonistes adrénergiques bêta-3 spécifiques
EP0801060A1 (fr) * 1996-04-09 1997-10-15 Pfizer Inc. Des agonistes bèta-3 adrénergiques hétérocycliques

Cited By (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001035947A2 (fr) * 1999-11-15 2001-05-25 Eli Lilly And Company Traitement des syndromes cachectiques au moyen de propanolamines aryloxy
WO2001035947A3 (fr) * 1999-11-15 2001-11-22 Lilly Co Eli Traitement des syndromes cachectiques au moyen de propanolamines aryloxy
EP1292564A2 (fr) * 2000-02-28 2003-03-19 Fujisawa Pharmaceutical Co., Ltd. Derive d'aminoalcool
WO2002000622A2 (fr) * 2000-06-27 2002-01-03 Fujisawa Pharmaceutical Co., Ltd. Nouveaux derives d'aminoalcool
WO2002000622A3 (fr) * 2000-06-27 2002-08-29 Fujisawa Pharmaceutical Co Nouveaux derives d'aminoalcool
US6730792B2 (en) 2000-07-13 2004-05-04 Eli Lilly And Company β3 adrenergic agonists
WO2002024635A2 (fr) * 2000-09-25 2002-03-28 Fujisawa Pharmaceutical Co., Ltd. Derives d'aminoalcool
WO2002024635A3 (fr) * 2000-09-25 2003-02-20 Fujisawa Pharmaceutical Co Derives d'aminoalcool
US6826033B2 (en) 2000-09-25 2004-11-30 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
US6825220B2 (en) 2000-11-10 2004-11-30 Eli Lilly And Company 3-Substituted oxindole β 3 agonists
US7122680B2 (en) 2000-11-10 2006-10-17 Eli Lilly And Company 3-Substituted oxindole β3 agonsists
US7208505B2 (en) 2001-08-14 2007-04-24 Eli Lilly And Company β3 adrenergic agonists
US6911463B2 (en) 2001-08-14 2005-06-28 Eli Lilly And Company 3-substituted oxindole β-3 agonists
US7087635B2 (en) 2001-08-14 2006-08-08 Eli Lilly And Company 3-substituted oxindole β3 agonists
US7452995B2 (en) 2001-11-13 2008-11-18 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
US7553971B2 (en) 2001-11-13 2009-06-30 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
US6670376B1 (en) 2001-11-13 2003-12-30 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
US6653323B2 (en) * 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
US7265127B2 (en) 2001-11-20 2007-09-04 Eli Lilly And Company β3 adrenergic agonists
US7071208B2 (en) 2001-11-20 2006-07-04 Eli Lilly And Company β3 Adrenergic agonists
US7253181B2 (en) 2001-11-20 2007-08-07 Eli Lilly And Company β3 adrenergic agonists
US7205407B2 (en) 2001-11-20 2007-04-17 Eli Lilly And Company 3-Substituted oxindole β3 agonists
US7241772B2 (en) 2001-11-20 2007-07-10 Eli Lilly And Company β3 adrenergic agonists
US7214697B2 (en) 2002-01-11 2007-05-08 Eli Lilly And Company 2-Oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists
US7009060B2 (en) 2002-01-11 2006-03-07 Eli Lilly And Company 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists
US6689888B2 (en) 2002-02-27 2004-02-10 Pfizer Inc. Processes and intermediates useful in preparing β3-adrenergic receptor agonists
US6919460B2 (en) 2002-02-27 2005-07-19 Pfizer Inc, Processes and intermediates useful in preparing β3-adrenergic receptor agonists
US6689800B2 (en) 2002-02-27 2004-02-10 Pfizer Inc. β3-adrenergic receptor agonist crystal forms, processes for the production thereof, and uses thereof
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
US7482491B2 (en) 2002-09-19 2009-01-27 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
HRP20050253B1 (hr) * 2002-09-19 2013-11-08 Eli Lilly And Company Diaril eteri kao opioid antagonisti opioidnih receptora
WO2004026305A1 (fr) * 2002-09-19 2004-04-01 Eli Lilly And Company Diaryle ethers utilises en tant qu'antagonistes de recepteur opioides
CN1312125C (zh) * 2002-09-19 2007-04-25 杏林制药株式会社 氨基醇衍生物及其加成盐以及免疫抑制剂
JP4646628B2 (ja) * 2002-09-19 2011-03-09 イーライ リリー アンド カンパニー オピオイド受容体アンタゴニストとしてのジアリールエーテル類
EA008861B1 (ru) * 2002-09-19 2007-08-31 Эли Лилли Энд Компани Диариловые эфиры в качестве антагониста опиоидного рецептора
WO2004026817A1 (fr) * 2002-09-19 2004-04-01 Kyorin Pharmaceutical Co., Ltd. Derive d'amino-alcool, sel d'addition de ce dernier et immunosuppresseur
US7763752B2 (en) 2002-09-19 2010-07-27 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivatives, salts thereof and immunosuppresive agents
EP2208727A1 (fr) * 2002-09-19 2010-07-21 Eli Lilly & Company Éthers de diaryl en tant qu'antagoniste de récepteur d'opioïde
US7381719B2 (en) 2002-09-19 2008-06-03 Eli Lilly And Company Diaryl ethers as opioid receptor antagonist
US7560463B2 (en) 2002-09-19 2009-07-14 Eli Lilly And Company Diaryl ethers as opioid receptor antagonists
US7531557B2 (en) 2002-09-19 2009-05-12 Eli Lilly And Company Diaryl ethers as opioid receptor antagonists
JP2006511474A (ja) * 2002-09-19 2006-04-06 イーライ・リリー・アンド・カンパニー オピオイド受容体アンタゴニストとしてのジアリールエーテル類
WO2004080996A1 (fr) * 2003-03-07 2004-09-23 Eli Lilly And Company Antagonistes des recepteurs opioides
US7396943B2 (en) 2003-03-07 2008-07-08 Eli Lilly And Company Opioid receptor antagonists
US7414132B2 (en) 2003-12-22 2008-08-19 Eli Lilly And Company Opioid receptor antagonists
WO2005066164A1 (fr) * 2003-12-22 2005-07-21 Eli Lilly And Company Antagonistes de recepteur d'opioides
US7977334B2 (en) 2004-04-30 2011-07-12 Boehringer Ingelheim International Gmbh Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions
US7662815B2 (en) 2004-07-21 2010-02-16 Theravance, Inc. Diaryl ether β2 adrenergic receptor agonists
US7317023B2 (en) 2004-07-21 2008-01-08 Theravance, Inc. Diaryl ether β2 adrenergic receptor agonists
DE102004050952A1 (de) * 2004-10-18 2006-04-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung von Beschwerden, die mit krankhaften Veränderungen oder Irritationen der Prostata verbunden sind
US8093247B2 (en) 2005-01-14 2012-01-10 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
US7816354B2 (en) 2005-12-15 2010-10-19 Astrazeneca Ab Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
WO2007078523A3 (fr) * 2005-12-15 2007-11-15 Astrazeneca Ab Composes d'oxazolidinone et leur utilisation en tant que potentialisateurs de recepteur de glutamate metabotropique
WO2007078523A2 (fr) * 2005-12-15 2007-07-12 Astrazeneca Ab Composes d'oxazolidinone et leur utilisation en tant que potentialisateurs de recepteur de glutamate metabotropique
US10206912B2 (en) 2006-07-14 2019-02-19 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
US11433061B2 (en) 2006-07-14 2022-09-06 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
US10532044B2 (en) 2006-07-14 2020-01-14 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
US9745312B2 (en) 2007-07-12 2017-08-29 Chemocentryx, Inc. Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
US10208050B2 (en) 2007-07-12 2019-02-19 Chemocentryx, Inc. Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
US7884110B2 (en) 2007-07-12 2011-02-08 Chemocentryx, Inc. Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
US9394307B2 (en) 2007-07-12 2016-07-19 Chemocentryx, Inc. Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
US10899765B2 (en) 2007-07-12 2021-01-26 Chemocentryx, Inc. Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
US8546408B2 (en) 2007-07-12 2013-10-01 Chemocentryx, Inc. Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
US10973809B2 (en) 2016-11-23 2021-04-13 Chemocentryx, Inc. Method of treating focal segmental glomerulosclerosis
US11324736B2 (en) 2016-11-23 2022-05-10 Chemocentryx, Inc. Method of Treating Focal Segmental Glomerulosclerosis
US10758540B2 (en) 2017-10-11 2020-09-01 Chemocentryx, Inc. Treatment of focal segmental glomerulosclerosis with CCR2 antagonists
US11382915B2 (en) 2017-10-11 2022-07-12 Chemocentryx, Inc. Treatment of focal segmental glomerulosclerosis with CCR2 antagonists

Also Published As

Publication number Publication date
JP2002534415A (ja) 2002-10-15
AUPP796798A0 (en) 1999-01-28
EP1140849A1 (fr) 2001-10-10

Similar Documents

Publication Publication Date Title
EP1140849A1 (fr) Amino-alcools et leur utilisation comme agonistes beta-3 adrenergiques
US6017919A (en) Compounds and pharmaceutical use thereof
CN108884029B (zh) Lsd1抑制剂
US20020143034A1 (en) Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
AU702832B2 (en) Substituted aryl piperazines as neurokinin antagonists
JP3507494B2 (ja) タキキニン拮抗薬
KR100231089B1 (ko) 혈소판 응집 억제제인 헤테로시클릭 유도체
CA2200981A1 (fr) Derives d'uree et leur utilisation comme inhibiteurs de l'acat
WO2002000622A2 (fr) Nouveaux derives d'aminoalcool
US20100179137A1 (en) Pyridone compound
US20080312237A1 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
KR20050071472A (ko) 퀴놀린 항생 물질 중간체의 제조 방법
JP2002512636A (ja) ウロキナーゼ阻害物質
US4505910A (en) Amino-pyrimidine derivatives, compositions and use
IL265790B2 (en) 2-Amino-n-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-trna synthetase
EP0130735B1 (fr) Dérivés de l'aminopyrimidine
EP2514748A1 (fr) 2,4-diaminoquinazolines utiles pour le traitement d'une atrophie musculaire spinale
WO2002094770A2 (fr) Derives d'amino-alcool
EP0921122A1 (fr) Nouveaux derives d'epoxysuccinamide et sels associes
US20040138462A1 (en) Aminoalcohol derivatives
US6812237B2 (en) N-substituted peptidyl nitriles as cysteine cathepsin inhibitors
KR101071748B1 (ko) 아미노알콜 유도체
JPH10114744A (ja) アミノグアニジンヒドラゾン誘導体、その製法及び剤
EP1142875A1 (fr) Derives de cinnamamide et compositions medicamenteuses renfermant ces derives
JPH0827113A (ja) ヘテロシクリルオキシベンゾイルグアニジン

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 592269

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999961305

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09868615

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999961305

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999961305

Country of ref document: EP